SCHEMBL3857735

SCHEMBL3857735

O=S(=O)(O)Oc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.41
KDM4E B2RXH2 5/20 0.41
P4HTM Q9NXG6 2/20 0.41
CCR1 P32246 2/20 0.41
CCR5 P51681 2/20 0.41
CCR8 P51685 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
METAP1 P53582 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41
DOHH Q9BU89 1/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
TSHR P16473 2/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
NAPRT Q6XQN6 2/20 0.38
SLC22A6 Q4U2R8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407987 0.85 LMNA (0.35) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL28588858 0.84 LMNA (0.38) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL6512183 0.83 KDM4E (0.44) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL9710399 0.81 FURIN (0.36) KDM4ETSHRSLC22A6HPGD
SCHEMBL1360826 0.79 LMNA (0.41) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL1407984 0.79 KDM4E (0.41) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL6220452 0.79 TDP1 (0.43) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL23611463 0.78 KDM4E (0.39) LMNAKDM4EP4HTMCCR1CCR5
SCHEMBL11554272 0.78 PTGS2 (0.40) LMNAKDM4EP4HTMCCR1CCR5
Sulfuric Acid SCHEMBL30276348 0.78 POLB (0.42) LMNAKDM4EP4HTMCCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115803418-A Water-soluble metal working oil 出光兴产株式会社 2023-03-14 CN disclosed
US-8198020-B2 Contacting target cell or noncellular molecular entity with phagocytic marker and moiety that binds to a component that is present on or at surface of target cell or noncellular molecular entity, thereby increasing level or density of phagocytic marker on target cell; marker comprises phosphatidylserine POTENTIA PHARMACEUTICALS, INC. (US) 2012-06-12 US disclosed
EP-1553086-B1 PROCESS FOR PRODUCING 5-(2 '-PYRIDYL)-2-PYRIDONE DERIVATIVE KURARAY CO (JP) 2009-10-07 EP disclosed
US-7479571-B2 Generation of combinatorial synthetic libraries and screening for novel proadhesins and nonadhesins CERNOFINA, LLC (US) 2009-01-20 US disclosed
US-7479571-B2 Generation of combinatorial synthetic libraries and screening for novel proadhesins and nonadhesins CERNOFINA, LLC (US) 2009-01-20 US disclosed
EP-1553086-A4 PROCESS FOR PRODUCING 5-(2 '-PYRIDYL)-2-PYRIDONE DERIVATIVE KURARAY CO (JP) 2007-04-25 EP disclosed
US-20050113297-A1 Compositions and methods for enhancing phagocytosis or phagocyte activity POTENTIA PHARMACEUTICALS, INC. 2005-05-26 US disclosed
WO-2005019429-A2 COMPOSITIONS AND METHODS FOR ENHANCING PHAGOCYTOSIS OR PHAGOCYTE ACTIVITY POTENTIA PHARMACEUTICALS, INC. (US) 2005-03-03 WO disclosed
WO-2004009553-A1 PROCESS FOR PRODUCING 5-(2'-PYRIDYL)-2-PYRIDONE DERIVATIVE KURARAY CO., LTD. (JP) 2004-01-29 WO disclosed
EP-0210227-B1 PYRIMIDINE SULFATES FOR HAIR GROWTH THE UPJOHN COMPANY (US) 1990-05-02 EP disclosed
EP-0210227-A1 PYRIMIDINE SULFATES FOR HAIR GROWTH. UPJOHN CO (US) 1987-02-04 EP disclosed
WO-1986004231-A1 PYRIMIDINE SULFATES FOR HAIR GROWTH THE UPJOHN COMPANY (US) 1986-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113297-A1 Compositions and methods for enhancing phagocytosis or phagocyte activity CD47, ANXA11, ANXA1 LMNA 1911/4885KDM4E 3736/4885P4HTM 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.